Stockscreener 앱 받기
0.36%
시간 외 거래:
전일 마감가:
$443.84
열려 있는:
$443.26
하루 거래량:
1.97M
Relative Volume:
0.75
시가총액:
$239.09B
수익:
$37.30B
순이익/손실:
$7.80B
주가수익비율:
30.76
EPS:
14.3793
순현금흐름:
$8.60B
1주 성능:
+3.99%
1개월 성능:
+17.60%
6개월 성능:
+15.07%
1년 성능:
+53.31%
1일 변동 폭
$441.26
$447.03
1주일 범위
$429.38
$447.03
52주 변동 폭
$269.77
$447.03
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
442.24 | 234.49B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,233.66 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.14 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.79 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
156.45 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.98 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Hold |
| 2026-03-10 | 개시 | Jefferies | Hold |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-01-20 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
FTC: Amgen patent arguments a “mockery of Section 2” - Global Competition Review
Amgen stock trades near record level as Q2 2026 results and dividend underpin valuation - Ad-hoc-news.de
Amgen (AMGN) Gets A Fresh Target, Is It Fully Priced? - Yahoo Finance
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? - The Motley Fool
Is Amgen (AMGN) Fully Priced As Analysts Lift Targets After Second Quarter Results? - simplywall.st
Bank of New York Mellon Corp Sells 97,857 Shares of Amgen Inc. $AMGN - MarketBeat
The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP - Yahoo Finance
AssuredPartners Investment Advisors LLC Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
B. Metzler seel. Sohn & Co. AG Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation - Ad-hoc-news.de
FTC Slams Amgen's Antitrust Shield Argument At 4th Circ. - Law360
Amgen Reaches Deal To End Ex-Worker's Tobacco Fee Fight - Law360
Amgen Target of Unusually High Options Trading (NASDAQ:AMGN) - MarketBeat
AMGN Maintains Overweight Rating by Piper Sandler -- Price Targe - GuruFocus
Rare disease drug recalled in Ireland after Japan deaths - RTE.ie
Incyte: Cheaper, Growing Faster, And The Market Keeps Paying Up For Amgen - Trefis
Amgen Named to The Wall Street Journal's Inaugural 2026 Best Companies for the Future List - Amgen
Amgen stock climbs to new highs on strong Q2 2026 growth - Ad-hoc-news.de
ETFs Investing in Amgen Inc. Stocks - TradingView
Better Bet Than Amgen Stock: INCY, NBIX Deliver More - Trefis
NewEdge Wealth LLC Reduces Holdings in Amgen Inc. $AMGN - MarketBeat
Main Street Financial Solutions LLC Takes $1.66 Million Position in Amgen Inc. $AMGN - MarketBeat
Wealthfront Advisers LLC Sells 6,410 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Great Lakes Advisors LLC - MarketBeat
Amgen Inc. $AMGN Shares Sold by Danske Bank A S - MarketBeat
First National Bank of Omaha Has $15.65 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc (AMGN) Shares Surge 4.0% -- What GF Score of 79 Tells Investors - GuruFocus
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy - Fierce Biotech
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? - 24/7 Wall St.
Amgen Inc Stock (AMGN) Moved Up by 3.19% on Aug 19: What Investors Need To Know - TradingKey
Amgen Stock Surges 3.5% as Healthcare Hits Record High - Yahoo Finance
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
AMGEN INC : ARGUS RESEARCH RAISES TARGET PRICE TO $460 - Bitget
Argus Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Trust Co. of Vermont Purchases New Position in Amgen Inc. $AMGN - MarketBeat
Pharma in hackers' crosshairs as Amgen breach moves to courts - The Pharma Letter
Commerzbank Aktiengesellschaft FI Acquires 14,693 Shares of Amgen Inc. $AMGN - MarketBeat
AMG National Trust Bank Has $3.57 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock extends 2026 rally as Q2 earnings beat and guidance lifted - Ad-hoc-news.de
ANTITRUST NEWS—4th Cir.: FTC: Amgen’s Enbrel patent-application deal is subject to antitrust scrutiny - vitallaw.com
TScan TherapeuticsAmgen To Terminate Research Collaboration And License Agreement With TScan TherapeuticsSEC Filing - TradingView
TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration - Stock Titan
Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Can Amgen (NASDAQ:AMGN) Extend Its Record-High Momentum? - Kalkine Media
Amgen (NASDAQ:AMGN) Results Put Growth Back In Focus - Kalkine Media
The Bull Case For Amgen (AMGN) Could Change Following Raised 2026 Earnings Guidance And Q2 BeatLearn Why - simplywall.st
Cantor Fitzgerald raises Amgen stock price target on core portfolio strength - Investing.com India
Amgen (NASDAQ:AMGN) Reaches New 1-Year High on Analyst Upgrade - MarketBeat
Amgen stock hits all-time high at 422.49 USD - Investing.com
Amgen stock hits all-time high at 422.49 USD By Investing.com - Investing.com India
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
암젠 주식 (AMGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
3.71%
자본화:
|
볼륨(24시간):